We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Neurocrine Biosciences in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein now expects ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) announced that its Board of Directors has authorized a stock ...

NasdaqGS:NBIX Earnings and Revenue History February 21st 2025 Examining Cashflow Against Neurocrine Biosciences' Earnings. As finance nerds would already know, the accrual ratio f ...

Biosciences announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine ...

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $11.7 billion biopharmaceutical company ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Wedbush analyst Laura Chico lowered the firm’s price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the ...

Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. Overall, the quarter showcased strong ...